Origin

China

Reliable choice, forever partner

Patner^TM Sirolimus-eluting Coronary Stent System is one of the most widely used DES in interventional cardiolgy in China. Introduced from 2005, more than 200, 000 Partner stents have been implanted in patients and extremely excellent clinical results have been achieved.

The successful delivery of safety and efficacy through the combination of a proven drug and a reliable polymer

A Proven Drug

Maximum DES Efficacy

1. Over 5 years of proven clinical application experience

2. Effective anti-restenosis and anti-inlammatory properties

A Reliable Polymer

Long-term safety

1. Advanced polymer-coating technology provides optimally controlled release of sirolimus that efficaciously inhibits intimal hyperplasia and restenosis.

2. PBMA/PEVA coating is a widely used biocompatible coating that provides an ideally controlled drug release

3. Only 6 micrometer thickness of polymer, thinner coating increases deliverability of stent

Advanced Stent Design

High confidence delivery

1.    Proprietary DOUBLE-HELIX stent structure is engineered for outstanding flexibility and conformability.

2.    Optimal thickness of stent strut provides favorable balance between radial strength and deliverability

3.    The unique 36 mm length makes it easy to achieve full coverage of long lesion.

Technical Parameters

Stent Material        316 LVM Stainless Steel

Strut Design   Open cell

Metall to Artery Ratio     15%

Recoil     <2%

Shortening     <1%

Strut Thickness      0.0045"

Delivery System

Catheter Design     Rapid Exchange

Balloon Compliance       Semi-compliant

Nominal Pressure   8 atm

Rated Burst Pressure     2.5-3.5mm 16 atm

4.0mm 14 atm

Distal Shaft (outer diameter)  2.8 Fr

Proximal Shaft (outer diameter)    2.3 Fr

Crossing Profile (3.0 mm diameter)      1.0 mm

Usable Catheter Length 135 cm

Minimum Guiding Catheter Compatibility     6 Fr / 0.070" I.D.

Guidewire Compatible    0.014"

Specifications:

Diameter(mm): 2.5,2.75,3.0,3.5,4.0

Length(mm):12,15,18,21,24,29,36

Supported by clinical data

FIM clinical study

Multi-center, randomized First In Man Trial to demonstrate safety and efficacy of Partner DES in coronary De Novo lesions. N=81.

Primary Endpoint: In-segment Late Loss at 6 months

Conclusions:

��span style="mso-tab-count: 1;">    Excellent device (100%) and procedure (100%) success.

��span style="mso-tab-count: 1;">    Low in-segment late loss (0.03±0.14 mm).

��span style="mso-tab-count: 1;">    No incidence of stent thrombosis.,

Partner Retrospective clinical study

Multi-center "real world" clinical study. N=1352.

Primary Endpoint: MACE at 12 month.

Conclusions:

��span style="mso-tab-count: 1;">    Low MACE rate (3.62%).

��span style="mso-tab-count: 1;">    Low revascularization rate (2.14%).

��span style="mso-tab-count: 1;">    Low stent thrombosis (0.66%).